DXR.NASDAQDaxor CORP

Form 4: Daxor Director Edward Feuer Granted 2,500 Stock Options Contingent on SEC Plan Approval

Sentiment:

Insider Transaction Report


Daxor Corp. Director Edward Feuer was granted 2,500 stock options with an exercise price of $9.29, contingent on SEC approval of an amendment to the company's 2020 Incentive Compensation Plan.

Delay expectedThe stock option grant is contingent on the approval of the Securities & Exchange Commission (SEC) to amend the Daxor Corporation 2020 Incentive Compensation Plan, which could introduce a delay in the finalization of the grant if approval is not timely or granted.

Summary

  • Edward Feuer, a Director of Daxor Corp. (DXR), was granted 2,500 stock options.
  • The options have an exercise price of $9.29 per share.
  • The grant date for these options is June 24, 2025, and they are set to expire on June 24, 2030.
  • The grant is contingent upon the Securities & Exchange Commission (SEC) approving an amendment to the Daxor Corporation 2020 Incentive Compensation Plan.
  • The stock options will vest in three installments: 833 options on June 24, 2025, 883 options on June 24, 2026, and 834 options on June 24, 2027.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is generally a neutral to slightly positive event, indicating continued alignment of interests, but the contingency on SEC approval introduces a minor element of uncertainty.

Positives

  • The grant of stock options to a director aligns management's interests with those of shareholders, incentivizing long-term performance and value creation.

Risks

  • The stock option grant is contingent on the Securities & Exchange Commission (SEC) approving an amendment to the Daxor Corporation 2020 Incentive Compensation Plan, introducing uncertainty regarding the finalization of the grant.

Future Outlook

The stock options are set to vest in three annual installments beginning June 24, 2025, and are contingent on future SEC approval of an amendment to the company's 2020 Incentive Compensation Plan.

Industry Context

This Form 4 filing reflects a standard practice of granting equity compensation to directors, a common method across industries to align leadership incentives with shareholder value creation. It does not, however, provide insights into broader industry trends beyond this specific corporate governance action.

Corporate Governance

Change TypeDescriptionEffective DateImpact Assessment
Policy AmendmentAmendment to the Daxor Corporation 2020 Incentive Compensation Plan, contingent on SEC approval.N/A (contingent)Aims to update the framework for equity compensation, potentially impacting future grants and director/employee incentives.

Related Party Transactions

  • The grant of stock options to Edward Feuer, a Director, constitutes a related party transaction as it involves compensation to an insider.

Stakeholder Impact

  • Shareholders: Potential positive impact due to increased alignment of director's interests with shareholder value creation.

Next Steps

  • SEC approval of the amendment to the Daxor Corporation 2020 Incentive Compensation Plan.
  • Vesting of 833 stock options on June 24, 2025.
  • Vesting of 883 stock options on June 24, 2026.
  • Vesting of 834 stock options on June 24, 2027.

Key Dates

DateDescription
06/24/2025Transaction date for stock option grant and first vesting installment (833 options).
06/26/2025Date of filing of the SEC Form 4.
06/24/2026Second vesting installment (883 options).
06/24/2027Third vesting installment (834 options).
06/24/2030Expiration date of the stock options.

Keywords

Daxor Corp, DXR, SEC Form 4, Stock Options, Insider Transaction, Beneficial Ownership, Director Compensation, Equity Grant, Incentive Compensation Plan, Edward Feuer

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.